|1.||Labow, Rosalind S: 2 articles (01/2008 - 01/2002)|
|2.||Santerre, J Paul: 2 articles (01/2008 - 01/2002)|
|3.||Dinnes, Donna Lee M: 1 article (01/2008)|
|4.||Sobel, Harold J: 1 article (01/2005)|
|5.||Watts, Laurel Melcher: 1 article (01/2005)|
|6.||Bissell, Elizabeth Cutler: 1 article (01/2005)|
|7.||Hubert, Doras D: 1 article (01/2005)|
|8.||Baylouny, Raymond A: 1 article (01/2005)|
|9.||Holiat, Stephen M: 1 article (01/2005)|
|10.||Yazdi, Ebrahim: 1 article (01/2005)|
|1.||Brain Neoplasms (Brain Tumor)
01/01/1983 - "A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors."
01/01/1995 - "Coupled with previous BTCG results, these trails suggest that PCNU is an active drug for brain tumors."
01/01/1987 - "PCNU and recurrent childhood brain tumors."
01/01/1983 - "Twenty-nine patients with recurrent primary malignant brain tumors were treated with 1-(2-chlorethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU) at an initial dose of 110 mg/m2 with subsequent doses determined by the degree of delayed toxicity. "
01/01/1987 - "PCNU, the latest nitrosourea analogue to be subjected to clinical trials, held promise as a superior chemotherapy agent for brain tumors because of more favorable biochemical and cytotoxic characteristics in laboratory studies. "
07/01/1983 - "This method has been applied to determine the in vitro rate of decomposition of PCNU in plasma and the plasma clearance of this drug from a cancer patient."
01/01/1987 - "A phase I study of the intracarotid administration of PCNU was conducted in patients with intracerebral tumors recurring after cranial radiation. "
01/01/1987 - "Thirty-nine children with a variety of recurrent primary CNS tumors, all of whom had evaluable disease, participated in a phase II PCNU trial. "
11/01/1983 - "In a phase I trial, 28 patients with advanced solid tumors were given PCNU daily for 5 days by iv infusion over 20 minutes at 6-week intervals. "
09/01/1981 - "PCNU was selected for clinical trials based on high activity in both standard and intracisternally transplanted murine tumors. "
07/01/1993 - "PCNU has no therapeutic advantage at this dose and schedule and does not warrant further study as a single agent for patients with high-grade glioma."
01/01/1990 - "Larger, randomized trials comparing PCNU to other nitrosoureas will be needed to assess its value as adjuvant therapy in patients with malignant gliomas. "
01/01/1990 - "Pilot study of PCNU and cranial radiation therapy in the treatment of patients with malignant gliomas."
01/01/1987 - "Modest activity of PCNU in recurrent childhood gliomas is confirmed. "
07/01/1984 - "PCNU treatment for recurrent malignant gliomas."
|4.||Colorectal Neoplasms (Colorectal Cancer)
08/01/1984 - "Phase II trial of PCNU in advanced colorectal carcinoma. "
02/01/1983 - "PCNU administered by the single-dose I.V. schedule as used in this study has very modest antitumor activity against colorectal cancer in humans."
11/01/1981 - "Phase II study of PCNU in colorectal carcinoma."
06/01/1988 - "PCNU: phase II evaluation in advanced colorectal carcinoma."
08/01/1984 - "In colorectal carcinoma, PCNU has limited clinical activity that does not appear to be superior to that of other nitrosoureas."
|5.||Melanoma (Melanoma, Malignant)
01/01/1985 - "Phase II trial of PCNU in advanced malignant melanoma: an Eastern Cooperative Oncology Group pilot study."
06/01/1985 - "Twelve patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with PCNU. "
01/01/1985 - "PCNU has comparable clinical activity to that of other nitrosoureas in patients with advanced melanoma."
01/01/1985 - "PCNU, a chloroethylnitrosourea with high alkylating activity, low carbamoylating activity, optimal octanol: water partition coefficient and broad activity in animal systems, was administered to 32 evaluable patients with measurable metastatic melanoma by brief intravenous infusions every six weeks. "
06/01/1985 - "A phase II trial of PCNU in patients with malignant melanoma and central nervous system metastases."
|7.||Interferon-alpha (Interferon Alfa)
|9.||Biocompatible Materials (Biomaterials)
|10.||Azacitidine (5 Azacytidine)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)